Anilawati Binti Mat Jelani Malaysia

Infectious Disease Consultant based at Hospital Raja Perempuan Zainab II (HRPZII), Kelantan with over 20 years of clinical experience and 15 years as an Infectious Disease Specialist. Current position: Serves as Head of the Infectious Disease Unit , Hospital Raja Perempuan Zainab II, Head of Infectious Disease Subspecialties for the Kelantan State Health Department, and State Infection Control and Antimicrobial Committee Coordinator for Kelantan, leading statewide IPC strategy, outbreak preparedness, and antimicrobial stewardship (AMS) initiatives. Also serves as a part-time lecturer in Infection Prevention & Control Advanced Diploma and HIV medicine Post Basic Caunseling, Part time lecturer for MSU Undergraduate Medical School. Contributing to undegraduate, postgraduate and post-basic healthcare training programmes. Active contributor to national and state-level infectious disease and Infection Prevention and Control (IPC) policy development under the Ministry of Health Malaysia Contributed to major national guidelines, including: • National Antibiotic Guideline (3rd & 4th Editions) • Malaysian Consensus Guidelines on Antiretroviral Therapy (2022 ,2026) • Clinical Practice Guidelines on Management of Dengue Infection in Adults (2015) • Multiple COVID-19 clinical management and healthcare worker protection annexes • Led state-level outbreak preparedness and response frameworks, including dengue and enteric fever operational guidelines • 2025 MOH Hospital Outbreak Management Team (OMT) Guideline, promoting structured outbreak governance, multidisciplinary coordination, and resilient IPC systems across healthcare facilities Publication: • Published and co-authored peer-reviewed studies in infectious diseases and IPC • Research on MDROs among critically ill COVID-19 patients and associated clinical outcomes • Multicentre research on risk factors and mortality in severe dengue patients requiring assisted ventilation. • Clinical study evaluating ivermectin efficacy in high-risk COVID-19 patients (I-TECH study). • Studies examining COVID-19 mortality patterns, comorbidities, and immunomodulatory therapy use.

Main Congress - Day 2

Time Session
2:50pm
4:00pm
Symposium 3A
Outbreak Management
Conference Hall 2

Main Congress - Day 3

Time Session
4:30pm
5:50pm
Symposium 7B
Invisible Hospital Reservoirs
Dr.Anilawati Binti Mat Jelani Chairperson Hospital Raja Perempuan Zainab IIMalaysia
Ms.Glenys Harrington Chairperson Infection Control Consultancy (ICC)Australia
Conference Hall 1